SEARCH:   Advanced

Blood, 3 December 2009, Vol. 114, No. 24, pp. 5044-5051. Prepublished online as a Blood First Edition Paper on September 9, 2009; DOI 10.1182/blood-2009-02-205989. This Article Full Text Full Text (PDF) Supplemental Table, Figures, and Videos All Versions of this Article: blood-2009-02-205989v1 114/24/5044    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Salles, I. I. Articles by Deckmyn, H. PubMed PubMed Citation Articles by Salles, I. I. Articles by Deckmyn, H. Related Collections Platelets and Thrombopoiesis Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  PLATELETS AND THROMBOPOIESIS Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are functionally active in an ex vivo flow model of thrombosis Isabelle I. Salles1, Tim Thijs1, Christine Brunaud2,3, Simon F. De Meyer1, Johan Thys4, Karen Vanhoorelbeke1, and Hans Deckmyn1 1 Laboratory for Thrombosis Research, Katholieke (KU) Universiteit Leuven Campus Kortrijk, Kortrijk; 2 Thrombogenics nv, Heverlee; 3 GlaxoSmithKline, Wavre; and 4 Algemeen Ziekenhuis Groeninge, Kortrijk, Belgium Xenotransplantation systems have been used with increasing success to better understand human hematopoiesis and thrombopoiesis. In this study, we demonstrate that production of human platelets in nonobese diabetic/severe combined immunodeficient mice after transplantation of unexpanded cord-blood CD34+ cells was detected within 10 days after transplantation, with the number of circulating human platelets peaking at 2 weeks (up to 87 x 103/µL). This rapid human platelet production was followed by a second wave of platelet formation 5 weeks after transplantation, with a population of 5% still detected after 8 weeks, attesting for long-term engraftment. Platelets issued from human hematopoietic stem cell progenitors are functional, as assessed by increased CD62P expression and PAC1 binding in response to collagen-related peptide and thrombin receptor-activating peptide activation and their ability to incorporate into thrombi formed on a collagen-coated surface in an ex vivo flow model of thrombosis. This interaction was abrogated by addition of inhibitory monoclonal antibodies against human glycoprotein Ib (GPIb) and GPIIb/IIIa. Thus, our mouse model with production of human platelets may be further explored to study the function of genetically modified platelets, but also to investigate the effect of stimulators or inhibitors of human thrombopoiesis in vivo. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Ready to analyze genetically modified human platelets Meinrad Gawaz Blood 2009 114: 4915-4916. [Full Text] [PDF] This article has been cited by other articles: M. Gawaz Ready to analyze genetically modified human platelets Blood, December 3, 2009; 114(24): 4915 - 4916. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020